Exai Bio: The company raised $70.6 million of Series A2 venture funding in a deal led by Section 32 and Casdin Capital on October 10, 2022, putting the company’s pre-money valuation at $60 million. Two Sigma Ventures also participated in the round. The company is a developer of a liquid biopsy platform designed to accurately diagnose cancer and inform personalized care treatments.
Matchpoint Therapeutics: The company raised $70 million of Series A venture funding in a deal led by Sanofi Ventures on October 14, 2022. Alexandria Venture Investments, Access Biotechnology, Atlas Venture, Vertex Ventures HC and Digitalis Ventures also participated in the round. The company is a developer of precision small molecule medicines intended to harness the power of covalency to transform the treatment of immune diseases.
Hexagon Bio: The company raised $67.3 million of Series B venture funding from undisclosed investors on October 11, 2022, putting the company’s pre-money valuation at $250 million. The company is a developer of synthetic biology platform designed to use data science to search for genomes for small molecule inhibitors of selected target proteins.
Viome Life Sciences: The company raised $67.0 million in Series C venture funding from Physician Partners, Ezaki Glico Company and Bulletproof Media on October 11, 2022, putting the company’s pre-money valuation at $272 million. Nomad Capital Partners, Eastward Capital Partners, Ocgrow Ventures and 6 other investors also participated in the round. The company is an operator of a biotechnology and healthcare business intended to prevent and reverse chronic diseases.
Ascidian Therapeutics: The company raised $50 million of Series A venture funding from Apple Tree Partners on October 12, 2022. The company is a developer of an RNA therapeutics platform intended to treat genetic diseases.
Bryn Pharma: The company raised $43.5 million of Series 3 venture funding from AllerFund Ventures, Chazen Capital Partners and Capstone Partners on October 11, 2022. The company is an operator of a biotechnology business intended to offer nasal-based epinephrine for anaphylaxis.
Monteris Medical: The company raised $35 million of venture funding from InnovaHealth Partners and other undisclosed investors on October 10, 2022. The company is a developer of magnetic resonance imaging-guided, laser-based systems designed for the ablation of brain lesions.
i2O Therapeutics: The company raised $33.5 million of Series A venture funding from undisclosed investors on October 11, 2022, putting the company’s pre-money valuation at $18 million. The company is a developer of oral biologics designed to treat metabolic and inflammatory diseases.
Vita Therapeutics: The company raised $31 million of Series B venture funding in a deal led by Cambrian and Solve FSHD on October 12, 2022. TEDCO, Riptide Ventures, Cedars-Sinai, and other undisclosed investors also participated in the round. The company is a developer of cellular therapeutics intended for the treatment of debilitating neuromuscular diseases and cancers.
Mablink: The company raised EUR 31 million of Series A venture funding in a deal led by Mérieux Equity Partners and Sofinnova Partners on October 14, 2022. Sham Innovation Santé, UI Investissement, Fournier-Majoie Foundation, Crédit Agricole Création, Elaia Partners and Angelor also participated in the round. The company is a developer of antibody-drug-conjugates designed to fight cancer.
Ochre Bio: The company raised $30 million of Series A venture funding from Hermes-Epitek, European Institute of Innovation and Technology and AixThera on October 10, 2022. LifeLink Ventures, Lifeforce Capital, Backed VC, Khosla Ventures, Selvedge Venture, Alice Zhang, Kristen Fortney and Marty Chavez also participated in the round. The company is a developer of ribonucleic acid therapies for chronic liver diseases intended to rejuvenate donors’ livers before transplant.
Mirror Biologics: The company received $20 million of development capital from Bradbury Asset Management on October 11, 2022. The company is a developer of novel immunotherapy drug products designed to incorporate living immune cells as the active ingredients.
Neuraptive Therapeutics: The company raised $19.5 million of venture funding from undisclosed investors on October 14, 2022. The company is a developer of a therapeutic technology intended to improve the speed and quality of recovery from peripheral nerve injury.
Thunder Biotech: The company raised $14 million of venture funding from undisclosed investors on October 11, 2022. The company is a developer of genetically engineered macrophage technology designed to treat cancer.
HAPPE Spine: The company raised $8.7 million of Series A venture funding from Celling Biosciences, Genesis Innovation Group and Biosciences Research and Commercialization Center on October 14, 2022, putting the company’s pre-money valuation at $4.7 million. The company is a developer of orthopedic implants designed to provide the optimal mechanical properties of polymer materials.
Curavit: The company raised $8.5 million of venture funding from Osage Venture Partners, Park City Angels and other undisclosed investors on October 13, 2022. The company is an operator of a clinical research business intended to design and execute decentralized or virtual trials.
BlueWillow Biologics: The company raised $5.9 million of venture funding in the form of equity and warrants from undisclosed investors on October 13, 2022. The company is a developer of vaccines designed to prevent respiratory diseases and offer mucosal immunity.
Carmine Therapeutics: The company raised an undisclosed amount of Series A venture funding from Simcere Pharmaceutical Group, Huagai Capital and EVX Ventures on October 13, 2022. Cystic Fibrosis Foundation also participated in the round. The company is a developer of a gene therapy platform designed to generate next-generation gene therapies by utilizing extracellular vesicles produced from red blood cells.
Puzzle Medical Devices: The company is in the process of raising Series A venture funding on October 10, 2022. The company is a manufacturer of a low-risk heart pump intended to cater to the needs of patients suffering from advanced heart failure.
